Cardiovascular risk assessment for osteoporosis patients considering Romosozumab

被引：2
|
作者：
Macrae, F. [1 ]
Clark, E. M. [2 ]
Walsh, K. [3 ]
Bailey, S. -J. [3 ]
Roy, M. [4 ]
Hardcastle, S. [5 ]
Cockill, C. [6 ]
Tobias, J. H. [2 ]
Faber, B. G. [2 ]
机构：
[1] Gloucestershire Hosp NHS Fdn Trust, Cardiol, Gloucester, England
[2] Univ Bristol, Musculoskeletal Res Unit, Bristol, England
[3] North Bristol Trust, Care Elderly, Bristol, England
[4] Univ Hosp Bristol & Weston, Rheumatol, Bristol, England
[5] Royal United Hosp Bath NHS Fdn Trust, Rheumatol, Bath, England
[6] Yeovil NHS Trust, Rheumatol, Yeovil, England
来源：
BONE | 2025年 / 190卷
关键词：
Osteoporosis; Fracture; Post-menopausal women;
D O I：
10.1016/j.bone.2024.117305
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
    Lim, Sian Yik
    WOMENS HEALTH, 2022, 18
  • [2] Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
    Chiu, Shi-Hsun
    Wu, Wen-Tien
    Yao, Ting-Kuo
    Peng, Cheng-Huan
    Yeh, Kuang-Ting
    BIOMEDICINES, 2024, 12 (12)
  • [3] Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
    Lim, Sian Yik
    WOMENS HEALTH, 2022, 18
  • [4] Romosozumab for the treatment of osteoporosis
    Bandeira, Leonardo
    Lewiecki, E. Michael
    Bilezikian, John P.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (02) : 255 - 263
  • [5] Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
    Lv, Fang
    Cai, Xiaoling
    Yang, Wenjia
    Gao, Leili
    Chen, Ling
    Wu, Jing
    Ji, Linong
    BONE, 2020, 130
  • [6] What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
    Reid, I. R.
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (12) : 1441 - 1443
  • [7] Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study
    Masuda, Soichiro
    Fukasawa, Toshiki
    Matsuda, Shuichi
    Yoshida, Satomi
    Kawakami, Koji
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (12) : 2165 - 2174
  • [8] Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
    Fixen, Cy
    Tunoa, Jennifer
    CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (01) : 15 - 22
  • [9] Romosozumab in the treatment of osteoporosis
    Kobza, Alexandra O.
    Papaioannou, Alexandra
    Lau, Arthur N.
    Adachi, Jonathan D.
    IMMUNOTHERAPY, 2020, 12 (13) : 965 - 981
  • [10] Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study
    Miyauchi, Akimitsu
    Hamaya, Etsuro
    Shimauchi, Junichiro
    Yoshinaga, Yoko
    Nishi, Kiyoshi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2024, 42 (01) : 77 - 89
12345